'Sulfur burps' and other GLP-1 things we're learning

TL;DR

GLP-1 weight loss drugs cause manageable side effects like sulfur burps while showing broader health benefits beyond weight loss, including brain and cardiovascular improvements.

Key Points

• 1.Sulfur burps are caused by delayed gastric emptying. GLP-1 drugs slow stomach motility, causing minor fermentation; nurse practitioner David White suggests pineapple or papaya enzymes as a practical remedy.
• 2.The 'big four' GI side effects are nausea, vomiting, constipation, and diarrhea. Absolute nausea rate is only about 20%, and side effects diminish over time as the body adjusts; slow dose titration makes the drugs quite tolerable.
• 3.These drugs are the only weight loss medications ever proven to produce dramatic, lasting results. Adam argues they should simply be called 'the weight loss drugs' since no prior drug class met any reasonable real-world standard of efficacy.
• 4.Muscle loss runs 25–35% of total weight lost, higher than the 25% expected from crash dieting. David White recommends patients prioritize protein intake and resistance training to preserve functional strength during treatment.
• 5.The drugs show health benefits even without weight loss. Clinical trials show improvements in cardiovascular, kidney, and brain health, and reductions in addiction and substance abuse disorders in people who didn't lose weight, suggesting weight is just one node in the metabolic syndrome web.
• 6.No receptor desensitization has been observed, unlike with opioids or cannabinoids. The SURPASS-CVOT trial of 15,000 patients over ~4.5 years showed stable weight loss and A1C control with no dose escalation needed, possibly because GLP-1 receptors are evolutionarily mission-critical — whale and bony fish glucagon still works in humans.
• 7.Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon simultaneously, may match bariatric surgery outcomes. Phase two data showed 24% weight loss at 48 weeks; a phase three arm showed 29% at 68 weeks with patients still losing, and longer-term data was due in June 2025.
• 8.Adam predicts obesity as a pandemic in developed countries will effectively end by 2035. David notes the US obesity rate has already flattened, possibly due to drug uptake, and drugs in development set a floor of 15–20% weight loss, enough to push many obese patients into merely overweight.